EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Probiotic Sources: 11

Saccharomyces boulardii

Also called: S. boulardii, Saccharomyces cerevisiae var. boulardii, S. boulardii CNCM I-745

Saccharomyces boulardii (Saccharomyces cerevisiae var. boulardii) is a probiotic yeast: a strain of S. cerevisiae with distinct genomic features. Products contain live yeast, dosed in colony-forming units (CFU); results apply to the strains studied, such as CNCM I-745.

Category
Probiotic
Forms
Live yeast cells (lyophilized products are listed in FDA's NDI list); amounts stated in CFU
Strongest evidence
A Strong
Reviewed
2026-10-30

Class 1 Well studied in people. A 2015 meta-analysis pooled 21 RCTs (4,780 participants) of S. boulardii versus placebo or no treatment for antibiotic-associated diarrhea in children and adults; the abstract names the organism as S. boulardii without a strain designation. [2]

Fact-checked 2026-10-30 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

4 topics studied1 body area · strongest grade A

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Saccharomyces boulardii does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Saccharomyces boulardii, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Antibiotic-associated diarrhea in children and adultsAA 2015 meta-analysis of 21 RCTs (4,780 participants) found S. boulardii lowered antibiotic-associated diarrhea risk from 18.7% to 8.5% versus placebo or no treatment (children 20.9% to 8.8%; adults 17.4% to 8.2%). [2]
Clostridium difficile-associated diarrheaCIn the 2015 meta-analysis of 21 RCTs, the reduction was significant in children (2 RCTs, 579 participants) but not in adults (9 RCTs, 1,441 participants; RR 0.8, 95% CI 0.47–1.34). [2]
Acute gastroenteritis in childrenBA 2020 meta-analysis of 29 RCTs found S. boulardii shortened diarrhea by 1.06 days (23 RCTs, 3,450 children) versus placebo or no treatment, but evidence quality was very low and heterogeneity high. [3]
Helicobacter pylori eradication therapy (added to standard antibiotics)BA 2015 meta-analysis of 11 RCTs (2,200 participants) found adding S. boulardii raised eradication from 71% to 80% and reduced therapy-related side effects, particularly diarrhea and nausea. [4]

Main constituents: S. cerevisiae var. boulardii: a S. cerevisiae strain distinguished by tetrasomy of chromosome XII, absence of intact Ty transposon elements and gene copy-number variations [1]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Pediatric acute infectious diarrhea: most commonly 10^9 to 10^10 CFU/day for 5–10 days in reviewed trials. [5]
  • Antibiotic-associated diarrhea: various doses were tested with no clear dose-dependent effects; ESPGHAN (2023) recommends 5 x 10^9 CFU/day or more of LGG or S. boulardii starting with antibiotics in children. [5]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    3 listed

    Antifungal medications; Antibiotics; Antibiotics (timing)

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    2 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    Stated

    Health Canada probiotics monograph (April 24, 2026), Saccharomyces boulardii / S.

    Details and sources
  • A systematic review of Saccharomyces fungemia (2005–2022) analyzed 108 cases; 73 (67.6%) had received S. boulardii probiotics. Associated risk factors included ICU stay, parenteral or enteral feeding, diarrhea and diabetes; all-cause mortality was 36.1%. [6]
  • ODS: at least 60 reports have been published since 1966 of fungemia associated with the use of probiotics that contain the yeast Saccharomyces cerevisiae. [5]
  • In a retrospective study (2005–2017), 6 of 10 patients with S. cerevisiae fungemia had S. boulardii probiotic prescriptions; mortality was 50%, and the authors suggest older age should be a contraindication. [7]
  • Health Canada's probiotics monograph: do not use if you have an immune-compromised condition (for example AIDS, lymphoma or long-term corticosteroid treatment). [8]
  • FDA (2023, probiotics in general): administering probiotics to preterm infants may cause infection or invasive and potentially fatal disease; FDA reported one infant death and more than two dozen other adverse events. [5]
Interactions

Interactions

Saccharomyces boulardii
From the table below 3 interactions the sources name. Tap one to read what happens. A line means a documented or possible interaction, not its size.
Known interactions of Saccharomyces boulardii
WithWhat happens
Antifungal medicationsHealth Canada's probiotics monograph directs that the yeasts in its Table 3, which include S. boulardii, be taken at least 2–3 hours before or after antifungal medications. [8]
AntibioticsA review states that S. boulardii CNCM I-745, because of its fungal nature, is intrinsically resistant to antibiotics and cannot promote the spread of antimicrobial resistance. [9]
Antibiotics (timing)Health Canada's direction to take probiotics 2–3 hours before or after antibiotics excludes S. cerevisiae and S. boulardii. [8]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • Health Canada requires each strain to be identified by phenotype and genotype, absence of virulence (including antifungal resistance review) to be shown, and at least 80% of the label-declared quantity to remain at the end of shelf life. [8]
  • US labels must list total microorganism weight, which can include live and dead cells; CFU may be listed voluntarily. [5]
Regulation

Regulatory status

  • Canada: listed in Health Canada's probiotics monograph (April 24, 2026) with the use 'helps to reduce the risk of antibiotic-associated diarrhea'. [8]
  • US: FDA's published NDI notification list has 2 entries naming Saccharomyces boulardii (earliest NDI 316 submitted 2005-02-08; most recent NDI 346 submitted 2005-09-08). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [10]
  • US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed; a firm is responsible for ensuring its products are not adulterated. [11]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Live Saccharomyces cerevisiae var. boulardii (a S. cerevisiae strain) Probiotic yeast [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 2 entries naming Saccharomyces boulardii (earliest NDI 316 submitted 2005-02-08; most recent NDI 346 submitted 2005-09-08). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P2]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of Saccharomyces boulardii was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P3]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • Antifungal medications: Health Canada's probiotics monograph directs that the yeasts in its Table 3, which include S. boulardii, be taken at least 2–3 hours before or after antifungal medications. [P4]
  • Antibiotics: A review states that S. boulardii CNCM I-745, because of its fungal nature, is intrinsically resistant to antibiotics and cannot promote the spread of antimicrobial resistance. [P5]
  • Antibiotics (timing): Health Canada's direction to take probiotics 2–3 hours before or after antibiotics excludes S. cerevisiae and S. boulardii. [P4]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P6]
  • Strain identity by phenotype and genotype (genome-based comparison to type strains and whole-genome strain characterization) — Required by Health Canada's probiotics monograph. [P4]
  • Viable count (CFU) at end of shelf life — Health Canada requires at least 80% of the label-declared quantity at the end of shelf life. [P4]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • Health Canada probiotics monograph (April 24, 2026), Saccharomyces boulardii / S. cerevisiae (all strains): risk reduction of antibiotic-associated diarrhea 1.0 x 10^10 to 3.0 x 10^10 CFU/day; all other uses at least 1.0 x 10^7 CFU/day. [P4]

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. Ting TY, et al. Molecular genetics and probiotic mechanisms of Saccharomyces cerevisiae var. boulardii. Probiotics Antimicrob Proteins 2026;18(2):3040-3054 (PMID 40705231), 2026-03. pubmed.ncbi.nlm.nih.gov
  2. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  3. IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
  4. Health Canada, NNHPD. Natural health product monograph: Probiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
  5. Kaźmierczak-Siedlecka K, et al. Saccharomyces boulardii CNCM I-745: a non-bacterial microorganism used as probiotic agent in supporting treatment of selected diseases. Curr Microbiol 2020;77(9):1987-1996 (PMID 32472262), 2020-09. pubmed.ncbi.nlm.nih.gov
  6. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources

Sources

  1. Ting TY, et al. Molecular genetics and probiotic mechanisms of Saccharomyces cerevisiae var. boulardii. Probiotics Antimicrob Proteins 2026;18(2):3040-3054 (PMID 40705231), 2026-03. pubmed.ncbi.nlm.nih.gov
  2. Szajewska H, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2015;42(7):793-801 (PMID 26216624), 2015-10. pubmed.ncbi.nlm.nih.gov
  3. Szajewska H, et al. Systematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children - a 2020 update. Aliment Pharmacol Ther 2020;51(7):678-688 (PMID 32056266), 2020-04. pubmed.ncbi.nlm.nih.gov
  4. Szajewska H, et al. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2015;41(12):1237-45 (PMID 25898944), 2015-06. pubmed.ncbi.nlm.nih.gov
  5. NIH Office of Dietary Supplements. Probiotics: Fact Sheet for Health Professionals (Updated March 25, 2025), 2025-03-25. ods.od.nih.gov
  6. Vinayagamoorthy K, et al. Epidemiology of Saccharomyces fungemia: a systematic review. Med Mycol 2023;61(2):myad014 (PMID 36806741), 2023-02-03. pubmed.ncbi.nlm.nih.gov
  7. Poncelet A, et al. Saccharomyces cerevisiae fungemia: risk factors, outcome and links with S. boulardii-containing probiotic administration. Infect Dis Now 2021;51(3):293-295 (PMID 33934809), 2021-05. pubmed.ncbi.nlm.nih.gov
  8. Health Canada, NNHPD. Natural health product monograph: Probiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
  9. Kaźmierczak-Siedlecka K, et al. Saccharomyces boulardii CNCM I-745: a non-bacterial microorganism used as probiotic agent in supporting treatment of selected diseases. Curr Microbiol 2020;77(9):1987-1996 (PMID 32472262), 2020-09. pubmed.ncbi.nlm.nih.gov
  10. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  11. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in probiotic: Akkermansia muciniphila (pasteurized) · Bacillus coagulans (Heyndrickxia coagulans) · Bifidobacterium animalis subsp. lactis BB-12 · Escherichia coli Nissle 1917 (EcN) · Lacticaseibacillus paracasei strain Shirota (LcS) · Lacticaseibacillus rhamnosus GG (LGG) · Lactiplantibacillus plantarum 299v · Limosilactobacillus reuteri DSM 17938 · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.